Hernandez, MH, Bote, V, Serra-LLovich, A, Cendros, M, Salazar, J, Mestres, C, Guijarro, S, Alvarez, A, Lamborena, C, Mendez, I, Sanchez, B, Hervas, A, Arranz, MJ. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders. Pharmacogenomics & Personalized Medicine. 2022; 15DOI:10.2147/PGPM.S377210. PMID:36393977. IF:1.900(Q4/9D).

Molto C., Tibau A., Bujosa A., Tapia J.C., Mittal A., Tamimi F., Amir E.. Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-25983-9. PMID:36494465. IF:(Q/D).

Isla D., Majem M.. A Paradigm Shift for Resectable Non-Small Cell Lung Cancer. ARCHIVOS DE BRONCONEUMOLOGIA. 2022; 58(12)DOI:10.1016/j.arbres.2022.04.004. PMID:35595655. IF:8.000(Q1/2D).

Argilés G., Valladares-Ayerbes M., Viéitez J.M., García-Paredes B., Rodríguez-Garrote M., Rivera F., Goldberg R.M., Ciardiello F., Tabernero J.M., Goldberg R., Argilés, Tabernero J., Mulet N., Limón M.L., Valladares M., Jiménez P., Vieitez J.M., Grávalos C., García-Alfonso P., Santos C., Páez D., Tobeña M., Sastre J., García Paredes B., Benavides M., Aranda E., Cano M.T., Loupakis F., Rguez Garrote M., Guillén C., Rivera M.F., Safont J., Hiret S., Bennouna J., Pannier D., Malka D., Falcone A., Cremolini C., The. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). EUROPEAN JOURNAL OF CANCER. 2022; 177DOI:10.1016/j.ejca.2022.09.037. PMID:36335783. IF:8.400(Q1/2D).

Martin-Broto J., Redondo A., Moura D.S., Valverde C., Morales J.M., Lopez-Pousa A., Martinez-Trufero J., Gutierrez A., Díaz-Beveridge R., Luna P., Martinez-Marin V., Marcilla D., Arribas I., Ledesma P., Lopez-Martin J.A., Di Lernia D., Zamora J., Hindi N.. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 2022; 13(1)DOI:10.1038/s41467-022-33975-6. PMID:36271011. IF:16.600(Q1/1D).

Blay J.Y., Palmerini E., Bollard J., Aguiar S., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Chs C.-S., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden, 5th, Chacón M., Clara-Altamirano M.A., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., Dei Tos A.P., Dominguez Malagon H.R., Donati D.M., Dufresne A., Eriksson M., Farias-Loza M., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gerderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Hindi N., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes A., Lopes David B.B., Lopez-Pousa A., Lutter G., Maki R.G., Martinez-Said H., Martinez-Tlahuel J.L., Mello C.A., Morales Pérez J.M., Moura D.S., Nakagawa S.A., Nascimento A.G., Ortiz-Cruz E.J., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Santos T.G., Scotlandi K., Mlg S., Soulé T., Stacchiotti S., Valverde C.M., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685)). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 180DOI:10.1016/j.critrevonc.2022.103827. PMID:36220678. IF:6.200(Q1/3D).